Circulating Small Noncoding RNA Biomarkers of Response to Triple Disease-modifying Antirheumatic Drug Therapy in White Women With Early Rheumatoid Arthritis
Andrew D Foers, Alexandra L Garnham, Gordon K Smyth, Susanna M Proudman, Lesley Cheng, Andrew F Hill, Ken C Pang, Ian P Wicks
The Journal of Rheumatology | J RHEUMATOL PUBL CO | Published : 2020
OBJECTIVE: To identify small noncoding RNA (sncRNA) serum biomarkers that predict response to triple disease-modifying antirheumatic drug (DMARD) therapy in patients with early rheumatoid arthritis (RA). METHODS: Early RA patients entered into a treat-to-target management algorithm, with triple DMARD therapy (methotrexate, sulfasalazine, hydroxychloroquine). Patients were assessed following 6 months of therapy and classified as European League Against Rheumatism responders or nonresponders. RNA was isolated from 42 archived serum samples, collected prior to commencement of triple DMARD therapy. Small RNA sequencing was performed and the reads mapped to annotations in a database of human sncR..View full abstract
This work was supported by the Reid Family Trust (IPW) and the Royal Children's Hospital Foundation (KCP).